StreetInsider.com News Articles

Form S-1/A HCW Biologics Inc.

Thu, 18 Jun 2026 13:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26664974.html

Form S-1/A HCW Biologics Inc.

Thu, 18 Jun 2026 13:05:00 -0400

si-local-file:///var/storage/secattach/20260618/26664974.html

Form 8-K HCW Biologics Inc. For: Jun 16

Tue, 16 Jun 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26650379.html

Form 8-K HCW Biologics Inc. For: Jun 16

Tue, 16 Jun 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260616/26650379.html

HCW Biologics reports positive Phase 1 data for alopecia drug HCW9302

Tue, 16 Jun 2026 07:00:15 -0400

HCW Biologics Inc. (NASDAQ: HCWB) announced preliminary positive results from the first two dose cohorts of its Phase 1 clinical trial evaluating HCW9302, an IL-2 based fusion immunotherapeutic, in patients with alopecia areata.

In the second dose cohort, all three participants who received a single subcutaneous dose of 3 micrograms per kilogram of body weight showed a reduction of at least 25% in Severity of Alopecia Tool (SALT) scores compared to baseline at four and/or nine weeks after dosing. All three patients in that cohort had mild alopecia.

Across both dose cohorts, no cases of capillary leak syndrome or cytokine release syndrome

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Tue, 16 Jun 2026 07:00:00 -0400

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells

Readout for dose-escalating clinical study for first two dose cohorts

All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration

Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts

HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Tue, 16 Jun 2026 07:00:00 -0400

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells

Readout for dose-escalating clinical study for first two dose cohorts

All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration

HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Tue, 16 Jun 2026 07:00:00 -0400

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells

Readout for dose-escalating clinical study for first two dose cohorts

All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration

HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Tue, 16 Jun 2026 07:00:00 -0400

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells

Readout for dose-escalating clinical study for first two dose cohorts

All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration

HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026

Form 8-K HCW Biologics Inc. For: Jun 15

Mon, 15 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260615/26647836.html

Form 8-K HCW Biologics Inc. For: Jun 15

Mon, 15 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260615/26647836.html

Form D HCW Biologics Inc.

Mon, 08 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260608/26617452.html

Form D HCW Biologics Inc.

Mon, 08 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260608/26617452.html

HCW Biologics (HCWB) files for 5.69M share offering by selling stockholders

Mon, 08 Jun 2026 10:13:34 -0400

HCW Biologics (NASDAQ: HCWB) has filed for up to 5,693,950 share offering by selling stockholders.

HCW Biologics (HCWB) files for 5.69M share offering by selling stockholders

Mon, 08 Jun 2026 10:13:34 -0400

HCW Biologics (NASDAQ: HCWB) has filed for up to 5,693,950 share offering by selling stockholders.

Form S-1 HCW Biologics Inc.

Mon, 08 Jun 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26615593.html

Form S-1 HCW Biologics Inc.

Mon, 08 Jun 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26615593.html

Form 8-K HCW Biologics Inc. For: May 29

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579237.html

Form 8-K HCW Biologics Inc. For: May 29

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579237.html

HCW Biologics Inc. (HCWB) PT Raised to $5 at Maxim Group

Thu, 28 May 2026 14:34:05 -0400

Maxim Group analyst Michael Okunewitch raised the price target on HCW Biologics Inc. (NASDAQ: HCWB) to $5.00 (from $2.00) while maintaining a Buy rating.

Form 4 HCW Biologics Inc. For: May 22 Filed by: Wong Hing C

Wed, 27 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260527/26559596.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: Wong Hing C

Wed, 27 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260527/26559596.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: GARRETT SCOTT T

Wed, 27 May 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260527/26559592.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: GARRETT SCOTT T

Wed, 27 May 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260527/26559592.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: Byam Rebecca

Wed, 27 May 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260527/26559589.html